| Ref ID | 922 |
| First Author | J. Modi |
| Journal | BRITISH JOURNAL OF ANAESTHESIA |
| Year Of Publishing | 2022 |
| URL | https://www.bjanaesthesia.org/article/S0007-0912(22)00449-4/fulltext |
| Keywords |
• Low methodological quality • Pain • Pharmacological • Harms |
| Problem(s) |
• Selective reporting of harms / safety / adverse events / side effects • Low methodological (AMSTAR) quality |
| Article Type | Empirical |
| Article Subtype | Cross-sectional survey/Methodological systematic review |
| First Author Country | United States |
| Checklists |
• AMSTAR 2 |
| Aim | To investigate the extent of harms reporting in systematic reviews (SRs) on ketorolac for perioperative pain. |
| Level of Investigation | Analytical |
| Summary of Findings | From 28 systematic reviews of ketorolac tromethamine to minimise postoperative opioid requirements indexed across MEDLINE (PubMed and Ovid), Embase, Epistemonikos, and the Cochrane Database of Systematic Reviews up to May 2022. Seven of the included systematic reviews (7/28, 25%) reported no harms and 17 systematic reviews (17/28, 60.7%) reported ≤50% of harms items. A significant association was found between completeness of harms reporting and whether harms were specified as a primary outcome (P<0.001). Methodological quality (AMSTAR-2) in 22 systematic reviews was appraised as ‘critically low’ (22/28, 78.6%), 5 as ‘low’ (5/28, 17.9%), and 1 as ‘high’ (1/28, 3.6%). |
| Number of systematic reviews included | 28 |
| Number of eligible systematic reviews assessed | 420 |
| Treatment impacted | No |
| Treatment impacted description | |
| Interpretation impacted | Not Applicable |
| Interpretation impacted description |